INTRODUCTION {#sec1}
============

Severe acute respiratory syndrome coronaviruses (SARS-CoV), including the original SARS-CoV (2003) and the novel SARS-CoV-2 (2019), are highly pathogenic viruses made up of structural proteins including spike, membrane, nucleocapsid, and envelope proteins ([@B16], [@B39]). Eighty percent of the genetic sequence of SARS-CoV (2003) is identical to SARS-CoV-2, the virus responsible for the global pandemic caused by the infectious disease COVID-19. The pathophysiology of CoV involves receptor-binding and proteolysis; these processes result in virus-cell fusion as previously detailed elsewhere ([@B29]). A key component of virus pathogenesis for SARS-CoV involves the cellular receptor angiotensin converting enzyme-2 (ACE2) ([@B23], [@B43]).

Emerging research has demonstrated that dietary intake can impact the expression and function of the *ACE2* gene ([@B30], [@B41]). Given our knowledge of the importance of ACE2 for SARS-CoV pathogenesis, coupled with preliminary knowledge about the impact of nutrition on *ACE2* gene expression and function, the purpose of this paper is to present the evidence for the biological plausibility of gene-diet interactions with *ACE2* modulating SARS-CoV illness severity.

BIOLOGICAL PLAUSIBILITY FOR GENE-DIET INTERACTIONS {#sec2}
==================================================

 {#sec2-1}

### ACE2 and SARS-CoV. {#sec2-1-1}

With ACE2 as the cellular receptor for SARS-CoV, the interaction between the virus and ACE2 impacts its entrance and clearance ([@B29], [@B45]). ACE is responsible for the cleavage of AngI into AngII ([@B34], [@B37]), and following this process, ACE2 generates Ang ([@B16], [@B23], [@B29], [@B30], [@B39], [@B41], [@B43]) from a single residue cleavage of AngII and then acts as a negative regulator ([@B8]). This phenomenon has been demonstrated in mouse models, whereby disrupting the murine *ACE2* gene leads to increased levels of AngII ([@B6]). ACE2 is attached to the cell membranes of lung, artery, heart, testicular, kidney, and intestinal cells ([@B7], [@B8], [@B14]). Alveolar epithelial type II cells of the lungs make up over 80% of the cells expressing ACE2 ([@B45]). ACE2 is also highly expressed on the liminal surface of intestinal epithelial cells ([@B15]), which may support the hypothesis that the COVID-19 pandemic may have begun with the consumption of an infected bat.

Acute respiratory distress syndrome is a form of acute lung injury that can result from SARS-CoV ([@B35]). With ACE2 as the cellular receptor for SARS-CoV, research demonstrates that ACE2 knockout mice are resistant to SARS-CoV infections ([@B17], [@B20]). Although ACE2 is needed for SARS-CoV host cell entry and replication ([@B17]), it is also important to disease progression and has been demonstrated to play a central (protective) role in determining symptom severity of acute respiratory distress syndrome ([@B18]). Accordingly, animal model research demonstrates that the disease severity of acute lung injury and acute respiratory distress syndrome were significantly more severe in mice with *ACE2* inactivated or knocked out after the infection with SARS-CoV compared with the wild-type mice. The knockout mice, with loss of ACE2 expression after being infected, experienced enhanced vascular permeability, increased lung edema, neutrophil accumulation, and worsened lung function. When these mice were then treated with catalytically active recombinant ACE2 protein, these symptoms improved ([@B18]). Several other studies have also demonstrated a therapeutic effect of ACE2 treatment on acute lung injury ([@B1], [@B4], [@B27]).

As such, the ACE2 cellular receptor has been proposed as a key target for the therapeutic treatment of SARS-CoV ([@B41], [@B43]). The virus has a strong binding affinity to human ACE2 ([@B22]), and ACE2 is required for host cell entry and viral replication ([@B43]). Following SARS-CoV infection, ACE2 expression is downregulated ([@B20]), which may play a causal role in the pathogenesis and disease progression ([@B17]). Overall, ACE2 activity is protective against SARS-CoV pathogenesis.

### Impact of dietary intake on ACE2 activity. {#sec2-1-2}

With a lack of studies in humans \[with the exception of one in vitro study in human aortic cells ([@B28])\], animal models inform our current knowledge base related to the impact of dietary factors on *ACE2*. ACE2 activity appears to be responsive to dietary fat and resveratrol, as further detailed below. Some preliminary research has also assessed the impact of high-fructose diets on ACE2 protein levels ([@B3]), and the impact of high-sodium diets on ACE2 receptor expression ([@B26]) but this work is only in its infancy.

The vast majority of the research on the impact of dietary intake on ACE2 activity has focused on dietary fat intake. Within these studies, the amount of dietary fat in the high-fat diet (HFD) groups varies from \~50 to 60% of total energy intake ([@B11]--[@B13], [@B41]). In a 10-wk dietary intervention study in mice, *ACE2* gene expression was examined in a control group (76% carbohydrate, 14% protein, 10% lipids) and an HFD group, in which the HFD was rich in saturated fat (36% carbohydrate, 14% protein, 50% lipids). The mRNA levels in mice livers were assessed, and it was observed that *ACE2* gene expression was reduced in the HFD group compared with the control group ([@B11]). Similarly, another study in the retroperitoneal adipose tissue of postnatal rats found that consumption of an HFD downregulated *ACE2* gene expression ([@B41]). Research has also demonstrated that an HFD can lead to reduced kidney ACE2 activity only in male mice and further demonstrated that the ovariectomy of female mice fed an HFD led to reduced adipose ACE2 activity ([@B13]). These nutrition-related changes in *ACE2* gene expression appear to impact further health-related outcomes. Accordingly, ACE2 deficiency resulted in increased systolic BP in male and female mice fed an HFD and promoted obesity-hypertension in female, ovariectomized mice fed an HFD ([@B13]). In a study of *ACE2* knockout compared with wild-type mice fed an HFD for 16 wk, knockout mice were more susceptible to beta cell dysfunction ([@B24]).

There are, however, some inconsistencies in the literature that should be noted. In a study on mice adipose tissue, ACE2 mRNA expression, activity and protein *increased* in response to an HFD ([@B12]). In a study on pancreatic islet cells of wild-type and *ACE2* knockout fed an HFD for 16 wk, there was no change in *ACE2* gene expression specifically in response to the HFD, but the authors suggest that *ACE2* gene expression was likely altered in other cells given their findings that *ACE2* gene therapy improved glycemia in the mice fed an HFD ([@B5]).

Beyond an HFD, there is consistent preliminary research demonstrating the potential for resveratrol to contribute to ACE2 activity. Resveratrol is a polyphenolic compound found in plant-based foods, such as red wine, berries, grapes, cocoa, and other foods. This compound is known for its potential protective effect against a number of conditions including cancer, cardiovascular disease, and respiratory illness ([@B2], [@B33], [@B42]). To date, three studies have assessed the impact of resveratrol on ACE2 activity. In a study of rats assigned to one of five different experimental diet groups, the rats who were fed 50 mg·kg^−1^·day of resveratrol demonstrated increased ACE2 protein level ([@B38]). In another study of mice fed an HFD compared with mice fed an HFD + resveratrol, there was significantly increased *ACE2* gene expression in mice fed the HFD + resveratrol. Therefore, the addition of dietary resveratrol may help to mitigate the detrimental impacts of high-fat diets on *ACE2* gene expression ([@B30]). Last, an in vitro study using human aortic smooth muscle cells demonstrated that incubation of cells with resveratrol for 24 h significantly increased *ACE2* gene and protein expression ([@B28]).

### Proposed gene-diet interactions of ACE2 and SARS-CoV in humans. {#sec2-1-3}

Hypotheses about human gene-diet interactions often stem from animal model and in vitro research. The abovementioned results suggest that interactions between *ACE2*, dietary fat, and SARS-CoV, as well as *ACE2*, resveratrol, and SARS-CoV influencing illness severity are biologically plausible in humans. Thus, we propose a potential mechanism whereby lower dietary fat and/or higher resveratrol intake may modulate responses to SARS-CoV, dependent on genetic variations in *ACE2*, which may then upregulate or downregulate its activity ([Fig. 1](#F0001){ref-type="fig"}). This hypothesis is supported by the abovementioned research demonstrating *1*) that ACE2 plays a key role in SARS-CoV disease progression ([@B18]) and *2*) the impact of diet on *ACE2* expression and function ([@B11], [@B13], [@B24], [@B28], [@B30], [@B38], [@B41]). This may help to explain the vast interindividual variability observed in SARS-CoV-2 illness severity in humans ([@B21]).

![Breakdown of proposed biological plausibility for interactions between dietary fat, resveratrol, angiotensin converting enzyme 2 (ACE2), and severe acute respiratory syndrome coronavirus (SARS-CoV) illness severity.](zh10052083580001){#F0001}

Furthermore, there is an association between HFD consumption and risk of developing diabetes mellitus (DM), suggesting that individuals with DM are more likely to consume an HFD ([@B9], [@B36]). As such, this proposed mechanism could add to the body of knowledge seeking to explain why SARS-CoV illness severity is greater in individuals with DM as well as in individuals with hypertension (HTN) ([@B29]). In addition, *ACE2* genetic variations contribute to type 2 DM and HTN risk, and thus high-risk genetic variants are more prevalent in these populations. Specific *ACE2* SNPs that have been previously demonstrated to be associated with type 2 DM and HTN (rs2106809, rs4646174, rs2074192, rs4240157, rs4646188, rs1978124, rs233575, rs2158083) are of interest to future research ([@B10], [@B25], [@B31], [@B32], [@B40], [@B44]). One study previously explored *ACE2* genetic variations between SARS-CoV (2003) cases, noncases, and contact and while no significant associations were found ([@B19]), it is possible that dietary intake confounded these results. In addition, to our knowledge this study has yet to be replicated for SARS-CoV-2. Several other potential SNPs of interest were outlined in this study ([@B19]), which would be worth exploring in future research involving ACE2 and SARS-CoV illness severity.

CONCLUSION {#sec3}
==========

Human studies are urgently needed to determine whether the proposed mechanism exists in a nonanimal model. If this proposed mechanism proves to be plausible in human studies, dietitians and other healthcare professionals could target dietary strategies with the aim of positively improving SARS-CoV illness severity in this current global COVID-19 pandemic.
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